We are dedicated to applying science for patients first. The diverse TESARO oncology pipeline and clinical study program have an unconditional focus—we address the urgent needs of the cancer community. Our concentrated vision enables us to dedicate all of our resources and energy to responsibly explore science, delivering transformative treatments and active support for people living with cancer and the healthcare providers who treat them. We are creating a diverse and balanced portfolio and platform that builds on the successes of our existing products, across tumor types and targets.
These combinations are the result of foresight and careful selection of the mechanisms of action we are investigating, including PARP inhibition and checkpoint inhibitors like PD-1, TIM-3, LAG-3, and other bi-specific inhibitors.1
Genes involved in DNA repair pathways frequently mutate in some cancers. Blocking poly (ADP-ribose) polymerase, or PARP, may help keep cancer cells from repairing their damaged DNA and ultimately lead to cancer cell death.2 We are investigating niraparib, our PARP inhibitor, for the treatment of ovarian cancer across different lines of therapy and in combination with other agents.
The goal of cancer immunotherapy is to eliminate cancer cells by initiating or reinitiating the anticancer immune response.3
And TESARO is developing a diversified family of antibodies that attacks tumors on multiple fronts.
We are exploring various mechanisms as monotherapy and in combination to treat a variety of cancers including, but not limited to, ovarian, endometrial, lung, and breast cancers, as well as other solid tumors.
Our studies are focused on science for people first, inspiring innovation in study designs and participant requirements—all in an effort to develop transformative treatments for those impacted by cancer.
Our roster of Carestone Clinical Studies focuses on finding breakthroughs for a variety of diseases including ovarian, endometrial, and lung cancers. Each study holds true to our core belief in Unconditional Care, which puts science for patients first.
References: 1. Chen DS, Mellman I. Oncology meets immunology: The cancer-immunity cycle. Immunity. 2013;39(1):1-10. doi:10.1016/j.immuni.2013.07.012. 2. NCI Dictionary of Cancer Terms: parp inhibitor. National Cancer Institute website. https://www.cancer.gov/publications/dictionaries/cancer-terms/def/parp-inhibitor. Accessed April 16, 2019. 3. NCI Dictionary of Cancer Terms: immunotherapy. National Cancer Institute website. https://www.cancer.gov/publications/dictionaries/cancer-terms/def/immunotherapy. Accessed April 16, 2019.